Molecular Biologic Staging of Esophageal Cancer

Thoracic Surgery Clinics

Volumn 16, Issue 4, 2006, Pages 317-327

  D'Amico, Thomas A ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CISPLATIN; FLUOROURACIL; GLUTATHIONE TRANSFERASE; METALLOTHIONEIN; MOLECULAR MARKER; PACLITAXEL; PLATINUM; PROTEIN P53; TUMOR MARKER;

BARRETT ESOPHAGUS; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CARCINOGENESIS; CIGARETTE SMOKING; DUODENOGASTRIC REFLUX; EARLY DIAGNOSIS; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS CANCER; GENE MUTATION; HUMAN; INCIDENCE; MISMATCH REPAIR; MORTALITY; NONHUMAN; PATHOPHYSIOLOGY; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RISK FACTOR; SENSITIVITY ANALYSIS; SINGLE STRAND CONFORMATION POLYMORPHISM;

ADENOCARCINOMA; CELL TRANSFORMATION, NEOPLASTIC; DRUG RESISTANCE, NEOPLASM; ESOPHAGEAL NEOPLASMS; HUMANS; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 37849189880     PISSN: 15474127     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thorsurg.2006.09.001     Document Type: Review

References (97)

1. Blot W.J., Devesa S.S., Kneller R.W., et al. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 265 (1991) 1287-1289
2. D'Amico T.A., and Harpole Jr. D.H. Molecular biology of esophageal cancer. Chest Surg Clin North Am 10 (2000) 451-469
3. Devesa S.S., Blot W.J., and Fraumeni J.F. Changing patterns of the incidence of esophageal and gastric carcinoma in the United States. Cancer 83 (1998) 2049-2053
4. Brown L.M., Silverman D.T., Pottern L.M., et al. Adenocarcinoma of the esophagus in white men in the United States: alcohol, tobacco, and socioeconomic factors. Cancer Causes Control 5 (1994) 333-340
5. Gammon M.D., Schoenberg J.B., Ahsan H., et al. Tobacco, alcohol, and socioeconomic status and adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst 89 (1997) 1277-1284
6. Kabat G.C., Ng S.K.C., and Wynder E.L. Tobacco, alcohol intake, and diet in relation to adenocarcinoma of the esophagus and gastric cardia. Cancer Causes Control 41 (1993) 123-132
7. Zhang Z.F., Kurtz R.C., Sun M., et al. Adenocarcinomas of the esophagus and gastric cardia: medical conditions, tobacco, alcohol, and socioeconomic factors. Cancer Epidemiol Biomarkers Prev 5 (1996) 761-768
8. Ribeiro U., Posner M.C., Safatle-Ribiero A.V., et al. Risk factors for squamous cell carcinoma of the esophagus. Br J Surg 83 (1996) 1174-1185
9. Spechler S.J., Robbins A.H., Rubins H.B., et al. Adenocarcinoma and Barrett's esophagus. Gastroenterology 87 (1984) 927-933
10. Altorki N.K., Oliveria S., and Schrump D.S. Epidemiology and molecular biology of Barrett's adenocarcinoma. Semin Surg Oncol 13 (1997) 270-280
11. Clark G.W., Smyrk T.C., Mirvish S.S., et al. Effect of gastroduodenal juice and dietary fat on the development of Barrett's esophagus and esophageal neoplasia: an experimental rat model. Ann Surg Oncol 1 (1994) 252-261
12. Lagergren J., Bergstrom R., Lingren A., et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 340 (1999) 825-831
13. Ireland A.P., Peters J.H., Smyrk T.C., et al. Gastric juice protects against the development of esophageal adenocarcinoma in the rat. Ann Surg 224 (1996) 358-371
14. Pera M., Trastek V.F., Carpenter H.A., et al. Influence of pancreatic and biliary reflux on the development of esophageal carcinoma. Ann Thorac Surg 55 (1993) 1386-1393
15. Kauer W.K.H., Peters J.H., DeMeester T.R., et al. Mixed reflux of gastric and duodenal juices is more harmful to the esophagus than gastric juice alone. Ann Surg 222 (1995) 525-531
16. Stein H.J., Barlow A.P., DeMeester T.R., et al. Complications of gastroesophageal reflux disease: role of the lower esophageal sphincter, esophageal acid and acid/alkaline exposure, and duodenogastric reflux. Ann Surg 216 (1992) 35-42
17. Stein H.J., Feussner H., Kauer W., et al. Alkaline gastroesophageal reflux: assessment by ambulatory esophageal aspiration and pH monitoring. Am J Surg 167 (1994) 163-168
18. Champion G., Richter J.E., Vaezi M.R., et al. Duodenogastroesophageal reflux: relationship to pH and importance in Barrett's esophagus. Gastroenterology 107 (1994) 747-754
19. Jochem V.A., Fuerst P.A., and Fromkes J.J. Familial Barrett's esophagus associated with adenocarcinoma. Gastroenterology 102 (1992) 1400-1402
20. Fahmy N., and King N.F. Barrett's esophagus: a acquired condition with genetic predisposition. Am J Gastroenterol 88 (1983) 1262-1265
21. Krishnadath K.K., Titanus H.W., Van Blankenstein M., et al. Accumulation of genetic abnormalities during neoplastic progression in Barrett's esophagus. Cancer Res 55 (1995) 1971-1976
22. Jankowski J.A., Wright N.A., Meltzer S.J., et al. Molecular evolution of the metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Am J Pathol 154 (1999) 965-973
23. Meltzer S.J., Yin J., Manin B., et al. Microsatellite instability occurs frequently in both diploid and aneuploid cell populations of Barrett's associated esophageal adenocarcinomas. Cancer Res 54 (1994) 3379-3382
24. Beer D.G., Morse M.A., and Orringer M.B. Metabolism and DNA binding of benzo(a)pyrene in Barrett's metaplasia. Proc Am Assoc Cancer Res 37 (1996) 128
25. Compton K.R., Orringer M.B., and Beer D.G. Induction of glutathione s-transferase-π in Barrett's metaplasia and Barrett's adenocarcinoma cell lines. Mol Carcinog 24 (1999) 128-136
26. Van Lieshout E.M.M., Roelofs H.M.J., Dekker S., et al. Polymorphic expression of the glutathione s-transferase pi gene and its susceptibility to Barrett's esophagus and esophageal carcinoma. Cancer Res 59 (1999) 586-589
27. Montesano R., Hollstein M., and Hainaut P. Genetic alterations in esophageal cancer and their relevance to etiology and pathogenesis: a review. Int J Cancer 69 (1996) 225-235
28. Symonds H., Krall L., Remington L., et al. p53 dependent apoptosis suppressed tumor growth and progression in vivo. Cell 78 (1994) 703-711
29. Neshat K., Sanchez C.A., Galipeau P.C., et al. Barrett's esophagus: a model of human neoplastic progression. Cold Spring Harb Symp Quant Biol 59 (1994) 577-583
30. Casson A.G., Tammenagi M., Eskandarian S., et al. p53 alterations in oesophageal cancer: association with clinicopathological features, risk factors, and survival. J Clin Pathol: Mol Pathol 51 (1998) 71-79
31. Schneider P.M., Casson A.G., Levin B., et al. Mutations of p53 in Barrett's esophagus and Barrett's cancer: a prospective study of ninety-eight cases. J Thorac Cardiovasc Surg 111 (1996) 323-333
32. Ramel S., Reid B.J., Sanchez C.A., et al. Evaluation of p53 protein expression in Barrett's esophagus by two-parameter flow cytometry. Gastroenterology 102 (1992) 1220-1228
33. Younes M., Ertan A., Lechago L.V., et al. p53 protein accumulation is a specific marker of malignant potential in Barrett's metaplasia. Dig Dis Sci 42 (1997) 697-701
34. Kubba A.K., Poole N.A., and Watson A. Role of p53 assessment in management of Barrett's esophagus. Dig Dis Sci 44 (1999) 659-677
35. Blount P.L., Ramel S., Raskind W.H., et al. 17p allelic deletions and p53 overexpression in Barrett's adenocarcinoma. Cancer Res 51 (1991) 5482-5486
36. Huang Y., Boynton R.F., Blount P.L., et al. Loss of heterozygosity involves multiple tumour suppressor genes in human esophageal cancers. Cancer Res 52 (1992) 6525-6530
37. Moskaluk C.A., and Rumpel C.A. Allelic deletion in 11p15 is a common occurrence in esophageal and gastric adenocarcinoma. Cancer 83 (1998) 232-239
38. Wu T., Watanabe T., Heitmiller R., et al. Genetic alterations in Barrett esophagus and adenocarcinomas of the esophagus and esophagogastric junction region. Am J Pathol 153 (1998) 287-294
39. Dolan K., Garde J., Gosney J., et al. Allelotype analysis of oesophageal adenocarcinoma: loss of heterozygosity occurs at multiple sites. Br J Cancer 78 (1998) 950-957
40. Yacoub L., Goldman H., and Odze R.D. Transforming growth factor-a, epidermal growth factor receptor, and MiB-1 expression in Barrett's associated neoplasia: correlation with prognosis. Mod Pathol 10 (1997) 105-112
41. Al Kasspooles M., Moore J.H., Orringer M., et al. Amplification and over-expression of EGFr and erb-B2 genes in human esophageal adenocarcinoma. Int J Cancer 54 (1993) 213-219
42. Shimada Y., Imamura M., Shibagaki I., et al. Genetic alterations in patients with esophageal cancer with short- and long-term survival rates after curative esophagectomy. Ann Surg 226 (1997) 162-168
43. Jiang W., Zhang Y.J., Kahn S.M., et al. Altered expression of the cyclin D1 and retinoblastoma genes in human esophageal cancer. Proc Natl Acad Sci USA 90 (1993) 9026-9030
44. Coggi G., Bosari S., Roncalli M., et al. p53 protein accumulation and p53 gene mutation in esophageal carcinoma: a molecular and immunohistochemical study with clinicopathologic correlations. Cancer 79 (1997) 425-432
45. Cawley H.M., Meltzer S.J., DeBenedetti V.M.G., et al. Anti-p-53 antibodies in patients with Barrett's esophagus or esophageal carcinoma can predate cancer diagnosis. Gastroenterol 115 (1998) 19-27
46. Kim R., Clarke M.R., Melhem M.R., et al. Expression of p53, PCNA, and c-erbB-2 in Barrett's metaplasia and adenocarcinoma. Dig Dis Sci 42 (1997) 2453-2462
47. Jones D.R., Davidson A.G., Summer C.L., et al. Potential application of p53 as an intermediate biomarker in Barrett's esophagus. Ann Thorac Surg 57 (1994) 598-603
48. Kim N.W., Piatyszek M.A., Prowse K.R., et al. Specific association of human telomerase activity with immortal cells and cancer. Science 266 (1994) 2011-2015
49. Takubo K., Nakamura K., Izumiyama N., et al. Telomerase activity in esophageal carcinoma. J Surg Oncol 66 (1997) 88-92
50. Bosset J.F., Gignoux M., Triboulet J.P., et al. Chemotherapy followed by surgery compared with surgery alone in squamous cell cancer of the esophagus. N Engl J Med 337 (1997) 161-167
51. Kelsen D.P., Ginsberg R., Pajak T., et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 339 (1998) 1979-1984
52. LePrise E., Etienne P.L., Meunier B., et al. A randomized study of chemotherapy, radiation therapy, and surgery versus surgery for localized squamous cell carcinoma of the esophagus. Cancer 73 (1994) 1779-1784
53. Urba S., Orringer M., Turrisi A., et al. A randomized trial comparing surgery to preoperative concomitant chemoradiation plus surgery in patients with resectable esophageal cancer. Proc Am Soc Clin Oncol 16 (1997) 277
54. Fiorica F., Di Bona D., Schepis F., et al. Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. Gut 53 (2004) 925-930
55. D'Amico T.A., Massey M., Herndon J.E., et al. A biological risk model for stage I lung cancer: immunohistochemical analysis of 408 patients with the use of ten molecular markers. J Thorac Cardiovasc Surg 117 (1999) 736-743
56. Potti A., Mukherjee S., Petersen R., et al. A genomic strategy to refine prognosis in early stage non-small cell lung cancer. N Engl J Med 355 (2006) 570-580
57. Sarbia M., Porschen R., and Borchard F. p53 protein expression and prognosis in squamous cell carcinoma of the esophagus. Cancer 74 (1994) 2218-2223
58. Hardwick R.H., Barham C.P., Ozua P., et al. Immunohistochemical detection of p53 and c-erb-B2 in oesophageal carcinoma. Eur J Surg Oncol 23 (1997) 30-35
59. Casson A.G., Evans S.C., Gillis A., et al. Clinical implications of p53 tumor suppressor gene mutation and protein expression in esophageal adenocarcinomas: results of a ten-year prospective study. J Thorac Cardiovasc Surg 125 (2003) 1121-1131
60. Patel D.D., Bhatavdekar J.M., Chikhlikar P.R., et al. Clinical significance of p53, nm23, and bcl-2 in T3-4N1M0 oesophageal carcinoma: an immunohistochemical approach. J Surg Oncol 65 (1997) 111-116
61. Lowe S.W., Ruley H.E., Jacks T., et al. p53-dependent apoptosis modulates the cytotoxicity of anticancer regimens. Cell 74 (1993) 957-967
62. Lowe S.W., Bodis S., McClatchey A., et al. p53 status and the efficacy of cancer therapy in vivo. Science 266 (1994) 807-810
63. Tanaka N., Ishihara M., Kitagawa M., et al. Cellular commitment to oncogene induced transformation or apoptosis. Cell 77 (1994) 829-839
64. Lam K.Y., Law S., Ma L.T., et al. Preoperative chemotherapy for squamous cell carcinoma of the oesophagus: do histological assessment and p53 overexpression predict chemoresponsiveness. Eur J Cancer 33 (1997) 1221-1225
65. Puglisi F., DiLoreto C., Panizzo R., et al. Expression of p53 and bcl-2 and response to preoperative chemotherapy and radiotherapy for locally advanced squamous cell carcinoma of the oesophagus. J Clin Pathol 49 (1996) 456-459
66. Ribeiro U., Finkelstein S.D., Safatle-Ribiero A.V., et al. p53 Sequence analysis predicts treatment response and outcome of patients with esophageal carcinoma. Cancer 83 (1998) 7-18
67. Aloia T.A., Harpole Jr. D.H., Reed C.E., et al. Tumor marker expression is predictive of survival in patients with esophageal cancer. Ann Thorac Surg 72 (2001) 859-866
68. Von Brevern M.C., Hollstein M.C., Cawley H.M., et al. Circulation anti-p53 antibodies in esophageal cancer patients are found predominantly in individuals with p53 core domain mutations in their tumors. Cancer Res 56 (1996) 4917-4921
69. Luketich J.D., Kassis E.S., Shriver S.P., et al. Detection of micrometastases in histologically negative lymph nodes in esophageal cancer. Ann Thorac Surg 66 (1998) 1715-1718
70. Izbicki J.R., Hosch S.B., Pichlmeier W., et al. Prognostic value of immunohistochemically identifiable tumor cells in lymph nodes of patients with completely resected esophageal cancer. N Engl J Med 337 (1997) 1188-1194
71. Parekh H., Wiesen K., and Simkins H. Acquisition of taxol resistance via p-glycoprotein and non-p-glycoprotein mediated mechanisms in human ovarian carcinoma cells. Biochem Pharmacol 53 (1997) 461-470
72. Gottesman M.M., and Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62 (1993) 385-427
73. Takebayashi Y., Akiyama S., Natsugoe S., et al. The expression of multidrug resistance protein in human gastrointestinal tract carcinomas. Cancer 82 (1997) 661-666
74. Cabral F., and Barlow S.B. Mechanisms by which mammalian cells acquire resistance to drugs that affect microtubule assembly. FASEB J 3 (1989) 1593-1599
75. Giannakakou P., Sackett D.L., Kang Y., et al. Paclitaxel-resistant human ovarian cancer cells have mutant b-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 272 (1997) 17118-17125
76. Monzo M., Rosell R., Sanchez J.J., et al. Paclitaxel resistance in non-small cell lung cancer associated with beta-tubulin gene mutations. J Clin Oncol 17 (1999) 1786-1793
77. Haldar S., Chintapalli J., and Croce C.M. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res 56 (1996) 1253-1255
78. Sarris A.H., Younes A., McLaughlin P., et al. Cyclosporine A does not reverse the clinical resistance to paclitaxel in patients with relapsed Hodgkin's lymphoma. J Clin Oncol 14 (1996) 233-239
79. Damia G., Guidi G., and D'Incalci M. Expression of genes involved in nucleoside excision repair and sensitivity to cisplatin and melphalan in human cancer cell lines. Eur J Cancer 34 (1998) 1783-1788
80. Crul M., Schellens J.H.M., Beijnen J.H., et al. Cisplatin resistance and DNA repair. Cancer Treat Rev 23 (1997) 341-366
81. Prolla T.A., Abuin A., and Bradley A. DNA mismatch repair deficient mice in cancer research. Semin Cancer Biol 7 (1996) 241-247
82. Nakajima T., Wang R., Nimura Y., et al. Expression of cytochrome p450 and glutathione s-transferase in human esophagus with squamous cell carcinoma. Carcinogenesis 17 (1996) 1477-1481
83. Barret J., and Hill B.T. DNA repair mechanisms associated with cellular resistance to antitumor drugs: potential novel targets. Anticancer Drugs 9 (1998) 105-123
84. Vaisman A., Varchenko M., Umar A., et al. The role of hMLH1, hMLH3, and hMLH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum DNA adducts. Cancer Res 58 (1998) 3579-3585
85. Aebi S., Kurdi-Haidar B., Gordon R., et al. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res 56 (1996) 3087-3090
86. Fink D., Nebel S., Aebi S., et al. The role of DNA mismatch repair in platinum drug resistance. Cancer Res 56 (1996) 4881-4886
87. Moreland N.J., Illand M., Kim Y.T., et al. Modulation of drug resistance mediated by loss of mismatch repair by the DNA polymerase inhibitor aphidicolin. Cancer Res 59 (1999) 2102-2106
88. Kelley S.L., Basu A., Teicher B.A., et al. Overexpression of metallothionein confers resistance to anticancer drugs. Science 241 (1998) 1813-1815
89. Satoh M., Cherian M.G., Imura N., et al. Modulation of resistance to anticancer drugs by inhibition of metallothionein synthesis. Cancer Res 54 (1994) 5255-5257
90. Timmer-Bosscha H., Mulder N.H., and deVries E.G.E. Modulation of cis-diamminedichloroplatinum (II) resistance: a review. Br J Cancer 66 (1992) 227-238
91. Hishikawa Y., Abe S., Kinugasa S., et al. Overexpression of metallothionein correlates with chemoresistance to cisplatin and prognosis in esophageal cancer. Oncology 54 (1997) 342-347
92. Holmes J., Wareing C., Jacobs A., et al. Glutathione s-transferase π expression in leukemia; a comparative analysis with mdr-1 data. Br J Cancer 62 (1990) 209-212
93. Satta T., Isobe K., Yamauchi M., et al. Expression of MDR1 and glutathione s-transferase p genes and chemosensitivities in human gastrointestinal tract cancer. Cancer 69 (1992) 941-946
94. Tominaga K., Arakawa T., Imano M., et al. Complete regression of recurrent esophageal carcinoma with reduced expression of glutathione s-transferase-p by treatment with continuous infusion of 5-fluorouracil and low-dose cisplatin infusion. Am J Gastroenterol 94 (1999) 1664-1668
95. Danenburg P.V. Thymidylate synthase: a target enzyme in cancer chemotherapy. Biochim Biophys Acta 473 (1997) 73-92
96. Yamachika T., Nakanishi H., Inada K., et al. A new prognostic factor for colorectal carcinoma, thymidylate synthase, and its therapeutic significance. Cancer 82 (1998) 70-77
97. Harpole Jr. D.H., Moore M.B., Herndon II J.E., et al. The prognostic value of molecular marker analysis in patients treated with trimodality therapy for esophageal cancer. Clin Cancer Res 7 (2001) 562-569